Price Alert

ACADIA Pharmaceuticals In... (ACAD)

NASDAQ: ACAD · Real-Time Price · USD

24.97

0.44 (1.79%)

At close: Aug 15, 2025, 11:20 AM

ACADIA Pharmaceuticals Statistics

Share Statistics

ACADIA Pharmaceuticals has 167.36M shares outstanding. The number of shares has increased by 0.9% in one year.

Shares Outstanding	167.36M
Shares Change (YoY)	0.9%
Shares Change (QoQ)	0.34%
Owned by Institutions (%)	99.99%
Shares Floating	166.9M
Failed to Deliver (FTD) Shares	898
FTD / Avg. Volume	0.04%

Short Selling Information

The latest short interest is 11.48M, so 6.86% of the outstanding shares have been sold short.

Short Interest	11.48M
Short % of Shares Out	6.86%
Short % of Float	10.8%
Short Ratio (days to cover)	5.82

Valuation Ratios

The PE ratio is 13.43 and the forward PE ratio is 30.37. ACADIA Pharmaceuticals's PEG ratio is -0.03.

PE Ratio	13.43
Forward PE	30.37
PS Ratio	3.17
Forward PS	3.5
PB Ratio	4.15
P/FCF Ratio	19.34
PEG Ratio	-0.03

Financial Ratio History

Enterprise Valuation

ACADIA Pharmaceuticals has an Enterprise Value (EV) of 2.77B.

EV / Sales	2.9
EV / EBITDA	27.69
EV / EBIT	17.58
EV / FCF	17.64

Financial Position

The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.07.

Current Ratio	2.38
Quick Ratio	2.32
Debt / Equity	0.07
Debt / EBITDA	0.52
Debt / FCF	0.33
Interest Coverage	0

Financial Efficiency

Return on Equity is 30.9% and Return on Invested Capital is 25.22%.

Return on Equity	30.9%
Return on Assets	19.07%
Return on Invested Capital	25.22%
Revenue Per Employee	$1.47M
Profits Per Employee	$346.79K
Employee Count	653
Asset Turnover	0.81
Inventory Turnover	3.73

Taxes

Income Tax	31.62M
Effective Tax Rate	12.25%

Stock Price Statistics

The stock price has increased by 62.39% in the last 52 weeks. The beta is 0.7, so ACADIA Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.7
52-Week Price Change	62.39%
50-Day Moving Average	22.38
200-Day Moving Average	18.5
Relative Strength Index (RSI)	67.21
Average Volume (20 Days)	2,136,288

Income Statement

In the last 12 months, ACADIA Pharmaceuticals had revenue of 957.8M and earned 226.45M in profits. Earnings per share was 1.37.

Revenue	957.8M
Gross Profit	875.96M
Operating Income	230.79M
Net Income	226.45M
EBITDA	100.16M
EBIT	84.28M
Earnings Per Share (EPS)	1.37

Full Income Statement

Balance Sheet

The company has 319.59M in cash and 51.99M in debt, giving a net cash position of 267.59M.

Cash & Cash Equivalents	319.59M
Total Debt	51.99M
Net Cash	267.59M
Retained Earnings	-2.2B
Total Assets	1.23B
Working Capital	630.53M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 157.72M and capital expenditures -523K, giving a free cash flow of 157.2M.

Operating Cash Flow	157.72M
Capital Expenditures	-523K
Free Cash Flow	157.2M
FCF Per Share	0.95

Full Cash Flow Statement

Margins

Gross margin is 91.46%, with operating and profit margins of 24.1% and 23.64%.

Gross Margin	91.46%
Operating Margin	24.1%
Pretax Margin	26.94%
Profit Margin	23.64%
EBITDA Margin	10.46%
EBIT Margin	24.1%
FCF Margin	16.41%

Dividends & Yields

ACAD does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	7.45%
FCF Yield	5.17%

Dividend Details

Analyst Forecast

The average price target for ACAD is $29, which is 16.8% higher than the current price. The consensus rating is "Buy".

Price Target	$29
Price Target Difference	16.8%
Analyst Consensus	Buy
Analyst Count	17

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	11.66
Graham Upside	-53.04%

Scores

Altman Z-Score	5.37
Piotroski F-Score	5